Pancreatic cancer is an increasingly lethal cancer and is often diagnosed at an advanced stage. Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic malignant tumors and is known as the "king of cancers". The degree of malignancy is very high, making diagnosis and treatment difficult. This is because pancreatic ductal adenocarcinoma tissue contains a large amount of fibrous tissue in addition to ductal epithelial cell components. The existence of fibrous tissue results in poor blood supply for pancreatic cancer, making it difficult for chemotherapy drugs to enter, so the treatment effect is not ideal. So there is a need to develop new and more effective treatments to cure this disease.
Pancreatic Cancer Antibodies We Offer
Antibodies can be used to target cancer cells and prevent tumor growth and progression. Antibodies have been widely used in malignant tumor research, such as pancreatic cancer, breast cancer, colon cancer, non-small cell lung cancer, etc. Clinical studies have shown that antibody therapy can not only effectively kill focus cells, but also activate the human immune system to improve the body's defense against cancer, while reducing treatment side effects and improving patient survival rates. The essence of antibody therapy is to use specific monoclonal antibodies synthesized in vitro to achieve the purpose of treatment by identifying, binding and eliminating disease-related antigens or disease cells expressing antigens. Alfa Cytology has extensive experience in pancreatic cancer research and can provide you with antibody products suitable for your research project.
Alfa Cytology is committed to providing customers with antibody products with strong targeting, high stability, and obvious effects for pancreatic cancer research. We can recommend the best antibody options based on our customers' needs. If you are interested in our products, please contact us for more details.
Grape seed extract
Catalog No.: PC0122
Description: Grape seed extract is a natural product, with anti-inflammatory and anti-proliferative effects. Grape seed extract shows inhibitory activity on the fat-metabolizing enzymes pancreatic lipase and lipoprotein lipase. Grape seed extract induces apoptotic in human colorectal cancer cells.
AES-135
Catalog No.: PC0123
Description: AES-135, a hydroxamic acid-based pan-HDAC inhibitor, extends survival in an orthotopic mouse model of pancreatic cancer.
Senaparib
Catalog No.: PC0124
Description: Senaparib (IMP4297) is a highly potent, selective, and orally active PARP1/2 inhibitor that exhibits strong antitumor activity in animal models.
Drozitumab
Catalog No.: PC0125
Description: Drozitumab (PRO 95780) is a human agonistic monoclonal antibody that binds the death receptor DR5 and has potent antitumor activity against rhabdomyosarcoma.
Istiratumab
Catalog No.: PC0126
Description: Istiratumab (M-6495) is a bispecific monoclonal antibody against IGF-1R and ErbB3 that induces degradation of IGF-1R and ErbB3 receptors through the proteasomal pathway and can be used in cancer research.
d-Sophoridine
Catalog No.: PC0127
Description: d-Sophoridine ((+)-Sophoridine) is the dextrorotary isomer of Sophoridine (HY-N1373) and induces apoptosis. Sophoridine has the potential to become a new, effective, and selective anti-tumor drug candidate for pancreatic cancer with good toxicity tolerance.
FTI-2148
Catalog No.: PC0128
Description: FTI-2148 is a RAS C-terminal mimetic bis-farnesyltransferase (FT-1) and geranylgeranyltransferase-1 (GGT-1) inhibitor.
Steviolbioside
Catalog No.: PC0129
Description: Steviolbioside is a rare sweetener that exists in stevia rebaudiana leaves. Steviolbioside presents inhibition on several human cancer cells and acts as potential remedy for human breast cancer.
Cathepsin L/S-IN-1
Catalog No.: PC0130
Description: Cathepsin L/S-IN-1 is a dual inhibitor of cathepsin L and cathepsin S with IC50 of 4.10 μM and 1.79 μM, respectively. Cathepsin L/S-IN-1 has significant anti-metastatic and invasive effects on pancreatic cancer BxPC-3 and PANC-1 cells.
Bazedoxifene-d4
Catalog No.: PC0131
Description: Bazedoxifene-d4 is deuterium-labeled Bazedoxifene, an oral, BBB-penetrating non-steroidal selective estrogen receptor modulator (SERM). Bazedoxifene is used in osteoporosis research. Bazedoxifene also serves as an inhibitor of the IL-6/GP130 protein-protein interaction and may be useful in pancreatic cancer research.
Bazedoxifene-d4 acetate
Catalog No.: PC0132
Description: Bazedoxifene-d4 (acetate) is deuterium-labeled Bazedoxifene, an oral, BBB-penetrating non-steroidal selective estrogen receptor modulator (SERM). Bazedoxifene is used in osteoporosis research. Bazedoxifene also acts as an inhibitor of the IL-6/GP130 protein-protein interaction and may be useful in pancreatic cancer research.
HYDAMTIQ
Catalog No.: PC0133
Description: HYDAMTIQ is a PARP-1/2 inhibitor (IC50: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits PARP activity in the lungs, is effective against allergen-induced cough and dyspnea, and suppresses bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancer, prostate and pancreatic cancer, and glioblastoma multiforme.
DpC
Catalog No.: PC0134
Description: DpC is an anti-tumor agent that inhibits cancer cell proliferation and has synergistic effects with various anti-cancer therapies.
2-Deoxy-2-fluoro-L-fucose
Catalog No.: PC0135
Description: 2-Deoxy-2-fluoro-L-fucose, an L-fucose analog, is a fucosylation inhibitor. 2-Deoxy-2-fluoro-L-fucose inhibits de novo synthesis of GDP-fucose in mammalian cells. Fucosylation is a relatively well-defined biomarker for progression in many human cancers; for example, pancreatic and hepatocellular carcinoma.
Sofituzumab vedotin
Catalog No.: PC0136
Description: Sofituzumab vedotin (DMUC5754A) is an MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin is used in cancer research.
Trigonelline chloride
Catalog No.: PC0137
Description: Trigonelline chloride, an alkaloid with potential antidiabetic activity, is a potent Nrf2 inhibitor that blocks Nrf2-dependent proteasome activity, thereby enhancing pancreatic cancer cell apoptosis.
Trigonelline
Catalog No.: PC0138
Description: Trigonelline is an alkaloid with potential antidiabetic activity that can be isolated from Trigonella foenum-graecum L or Leonurus artemisia. Trigonelline is a potent Nrf2 inhibitor that blocks Nrf2-dependent proteasome activity, thereby enhancing apoptosis in pancreatic cancer cells.
Ki16198
Catalog No.: PC0139
Description: Ki16198, a potent orally active LPA receptor antagonist that inhibits LPA1- and LPA3-induced phosphoinositide production, is effective against pancreatic cancer tumorigenesis and metastasis in vivo.
Certepetide
Catalog No.: PC0140
Description: Certepetide (CEND-1) is a bifunctional cyclic peptide, tumor penetration enhancer that interacts with αv-integrin through the RGD motif and by activating NRP-1, and transforms the solid tumor microenvironment into a temporary drug pipeline. Certepetide accumulates in tumors and is used in studies of pancreatic cancer and other solid tumors.
Bazedoxifene acetate
Catalog No.: PC0141
Description: Bazedoxifeneacetate (TSE-424acetate) is an oral, non-steroidal selective estrogen receptor modulator. Bazedoxifene acetate also acts as an inhibitor of IL-6/GP130 protein-protein interaction and may be useful in pancreatic cancer research.
